Outlier in a BE study [Outliers]

posted by Helmut Homepage – Vienna, Austria, 2014-01-16 15:54 (3426 d 08:57 ago) – Posting: # 12181
Views: 8,834

Hi Kumar,

❝ FDA does not encourage redosing to handle outliers subjects incase of non-replicate design study…


❝ … wherein you may carry out redosing incase of replicate design.

I don’t think so – at least in a fully replicated design (see this post). In a partial replicate – if the “outlier” occurred after T – I would not perform a re-dosing study without contacting FDA OGD’s review stuff beforehand.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
 Admin contact
22,616 posts in 4,740 threads, 1,613 registered users;
20 visitors (0 registered, 20 guests [including 13 identified bots]).
Forum time: 01:51 CEST (Europe/Vienna)

Biostatistician. One who has neither the intellect for mathematics
nor the commitment for medicine but likes to dabble in both.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz